In the latest trove of promising Phase III data for Amgen's T-Vec, the cancer-fighting virus increased overall survival by four months compared to standard growth factor therapy, driving optimism that the drug can win approval and make some noise in the melanoma market.
Merck highlighted evidence of a rising response rate to its closely watched immunotherapy MK-3475, spotlighting an 81% overall survival rate for advanced melanoma patients after 12 months of therapy with 41% of all patients demonstrating tumor shrinkage--rising to an impressive 51% for one group at the high end of the dose range.
With Gilead's pioneering hepatitis C drug sofosbuvir moving closer to a likely approval and a megablockbuster market, AbbVie is looming from behind with some promising results from the first of 6 Phase III studies of its breakthrough triple-threat therapy.
Promising results from early-stage work on Zafgen's weight drug beloranib clear a path to a Phase IIb trial that can fine-tune the dose while taking more time to gauge the long-term impact of its treatment on weight and set the right tone for ongoing talks with investors about a new financing round for the biotech.
Theravance CEO Rick Winningham put out the word today that its drug TD-9855 flunked a mid-stage study for attention deficit/hyperactivity disorder, adding that the biotech planned to scrap the program while continuing a separate study for fibromyalgia.
The pharma giant reported that the drug did not produce a statistically significant improvement in the risk of heart attack, stroke or death, though it added that "greater reductions" for some of the secondary endpoints warranted careful follow-up review as investigators considered its potential.
A little more than a year since its last lead therapy bit the dust, Zalicus today reported that its new lead drug foundered in a pair of mid-stage studies and will join the company's growing scrap heap. The news triggered a rout on Wall Street, with shares in meltdown mode after the news hit.
Shares of already badly battered Coronado Biosciences stock took a fresh dive this morning after the biotech announced that the second mid-stage study of its experimental Crohn's drug had to be scrapped after independent monitors concluded that the therapy wasn't helping patients.
Shares of Geron doubled this morning after the company posted an abstract of promising results from a small study at the Mayo Clinic conducted on imetelstat for myelofibrosis.
Ocera Therapeutics raised $28 million from a group of venture investors backing the biotech's work on orphan liver diseases. The San Diego-based biotech's lead therapy is OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy, which is slated to start a Phase IIb study later this year.